My first question is, since CDMO can be a lumpy business, where late -stage molecules may or may not flow through commercial. So what are the opportunities you are exploring in, say, the generic API space to improve our capacity utilization? And if you could highlight any potential large molecules in the pipeline in the event that we do have large spare capacity
Sure.
My first question is, since CDMO can be a lumpy business, where late -stage molecules may or may not flow through commercial. So what are the opportunities you are exploring in, say, the generic API space to improve our capacity utilization? And if you could highlight any potential large molecules in the pipeline in the event that we do have large spare capacity
Sure.
We have launched about 150 new products, new SKUs in the consumer health business over the last three years. So, what is the mix of these new launches say under our power brands versus the rest of our portfolio?
And just to sort of understand this better, how do we measure the success of these new launches in terms of like sales targets, field source, productivity, incremental promotional spends, margins, inventory? If you could give us some…
My first question is could you possibly outline a debt reduction road map for the next, say, three to five years? We have obviously post the rights issue , we have done we have reduced the leverage. What would be our sort of long-term road map regarding debt reduction?
And regarding the cash flows, I think we generated almost, like, I think 500 crores of operating cash flows this first half . What would be the quantum of CAPEX we see ourselves sort of undertaking over the next two to three years based on the order inflows you are getting from some innovative customers our CAPEX requirements in the complex injectables? How do you see sort of our cash flow being deployed there versus we get a better understanding of what can be used for debt reduction etc., right? So, if you could help us there?